{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T02:12:55Z","timestamp":1794881575727,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T00:00:00Z","timestamp":1758067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","award":["3200B0\u2013105993"],"award-info":[{"award-number":["3200B0\u2013105993"]}],"id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002066","name":"GlaxoSmithKline foundation","doi-asserted-by":"publisher","award":["3200B0-118308"],"award-info":[{"award-number":["3200B0-118308"]}],"id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Caffeine metabolic ratios (CMR) following monitored caffeine intake are the gold standard to probe cytochrome P450 (CYP) 1A2 activity, which metabolizes antipsychotics like clozapine and olanzapine. Given caffeine\u2019s ubiquity, we tested whether random CMR from dietary caffeine were associated with (1) clinical, genetic, and epigenetic factors linked to CYP1A2 activity; (2) plasma concentrations of clozapine and olanzapine; and (3) psychotropic treatment response. First, we analyzed two population-based studies (CoLaus|PsyCoLaus, N\u2009=\u20094898; SKIPOGH, N\u2009=\u20092054) to investigate random CMR associations with clinical, genome-wide, and epigenome-wide factors associated with CYP1A2 activity. Second, in psychiatric cohorts, we tested CMR associations with dose-normalized plasma concentrations (C\/D) of clozapine (N\u2009=\u2009164) and olanzapine (N\u2009=\u2009222) and with psychotropic treatment response, including hospital admission risk (N\u2009=\u20091019) and prolonged stays (N\u2009=\u20091349). CMR were positively associated with age, CYP1A2 inducers including smoking, and negatively with female sex. CMR were negatively associated with clozapine C\/D, explaining up to 14.9% of the variance; over six-fold the variance explained by genetic factors. A one-unit increase in CMR was associated with a 26% increased likelihood of hospital admission (p\u2009=\u20090.002) and reduced short-stay chance by 11% (p\u2009&lt;\u200910\n                    <jats:sup>\u22123<\/jats:sup>\n                    ). Random CMR provides a useful method to probe CYP1A2 activity, contributing, alongside other variables, to personalizing clozapine doses and identifying psychiatric patients at risk of hospital admission and lengthy stays. Incorporating routine measurement of random CMR before introduction of clozapine could be considered to allow early assessment of CYP1A2 activity, a key determinant of personalized clozapine dose titration.\n                  <\/jats:p>","DOI":"10.1038\/s41380-025-03256-x","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:53:33Z","timestamp":1758128013000},"page":"1420-1430","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Dietary caffeine to assess CYP1A2 activity, tailor clozapine doses, and predict treatment response: genetic, epigenetic and clinical analyses"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8029-2418","authenticated-orcid":false,"given":"Nermine","family":"Laaboub","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Vandenberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8350-9416","authenticated-orcid":false,"given":"Nicolas","family":"Ansermot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5579-0199","authenticated-orcid":false,"given":"Marianna","family":"Piras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0238-2976","authenticated-orcid":false,"given":"Setareh","family":"Ranjbar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusan","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4525-4608","authenticated-orcid":false,"given":"Giorgio","family":"Pistis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Vandenberghe-D\u00fcrr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3053-484X","authenticated-orcid":false,"given":"Marie-Pierre F.","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-8500","authenticated-orcid":false,"given":"Pedro","family":"Marques-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belen","family":"Ponte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menno","family":"Pruijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska","family":"Gamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7852-3803","authenticated-orcid":false,"given":"Armin","family":"von Gunten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin Jessica","family":"Plessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Conus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3790-7194","authenticated-orcid":false,"given":"S\u00e9verine","family":"Crettol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vollenweider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5689-4259","authenticated-orcid":false,"given":"Martin","family":"Preisig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murielle","family":"Bochud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-0230","authenticated-orcid":false,"given":"Chin B.","family":"Eap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"3256_CR1","unstructured":"Landi MT, Sinha R, Lang NP, Kadlubar FF Human cytochrome P4501A2. IARC Sci Publ. 1999;148:173\u201395."},{"key":"3256_CR2","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1002\/cpt.2412","volume":"110","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Terrier J, Gloor Y, Curtin F, Rollason V, Desmeules JA, et al. Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther. 2021;110:1358\u201367. https:\/\/doi.org\/10.1002\/cpt.2412","journal-title":"Clin Pharmacol Ther"},{"key":"3256_CR3","doi-asserted-by":"publisher","first-page":"e1002033","DOI":"10.1371\/journal.pgen.1002033","volume":"7","author":"MC Cornelis","year":"2011","unstructured":"Cornelis MC, Monda KL, Yu K, Paynter N, Azzato EM, Bennett SN, et al. Genome-Wide meta-analysis identifies regions on 7p21 (AHR) and 15q24 (CYP1A2) as determinants of habitual caffeine consumption. PLOS Genet. 2011;7:e1002033 https:\/\/doi.org\/10.1371\/journal.pgen.1002033","journal-title":"PLOS Genet"},{"key":"3256_CR4","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/hmg\/ddr086","volume":"20","author":"P Sulem","year":"2011","unstructured":"Sulem P, Gudbjartsson DF, Geller F, Prokopenko I, Feenstra B, Aben KKH, et al. Sequence variants at CYP1A1-CYP1A2 and AHR associate with coffee consumption. Hum Mol Genet. 2011;20:2071\u20137. https:\/\/doi.org\/10.1093\/hmg\/ddr086","journal-title":"Hum Mol Genet"},{"key":"3256_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/tpj.2009.4","volume":"9","author":"R Ghotbi","year":"2009","unstructured":"Ghotbi R, Gomez A, Milani L, Tybring G, Syv\u00e4nen AC, Bertilsson L, et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J. 2009;9:208\u201317. https:\/\/doi.org\/10.1038\/tpj.2009.4","journal-title":"Pharmacogenomics J"},{"key":"3256_CR6","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","volume":"97","author":"MS Faber","year":"2005","unstructured":"Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? BCPT. 2005;97:125\u201334. https:\/\/doi.org\/10.1111\/j.1742-7843.2005.pto_973160.x","journal-title":"BCPT"},{"key":"3256_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/00008571-199406000-00001","volume":"4","author":"U Fuhr","year":"1994","unstructured":"Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine\/caffeine ratio in plasma and in saliva. Pharmacogenetics. 1994;4:109\u201316. https:\/\/doi.org\/10.1097\/00008571-199406000-00001","journal-title":"Pharmacogenetics"},{"key":"3256_CR8","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1007\/s00394-024-03351-9","volume":"63","author":"N Laaboub","year":"2024","unstructured":"Laaboub N, Ranjbar S, Strippoli MPF, Marques-Vidal P, Estoppey-Younes S, Ponte B, et al. Self-reported caffeine consumption miss-matched consumption measured by plasma levels of caffeine and its metabolites: results from two population-based studies. Eur J Nutr. 2024;63:1555\u201364. https:\/\/doi.org\/10.1007\/s00394-024-03351-9","journal-title":"Eur J Nutr"},{"key":"3256_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 2019;394:939\u201351. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"3256_CR10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","volume":"51","author":"C Hiemke","year":"2018","unstructured":"Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51:9\u201362. https:\/\/doi.org\/10.1055\/s-0043-116492","journal-title":"Pharmacopsychiatry"},{"key":"3256_CR11","doi-asserted-by":"publisher","first-page":"22r14626","DOI":"10.4088\/JCP.22r14626","volume":"84","author":"K Wesner","year":"2023","unstructured":"Wesner K, Hiemke C, Bergemann N, et al. Therapeutic reference range for olanzapine in schizophrenia: systematic review on blood concentrations, clinical effects, and dopamine receptor occupancy. J Clin Psychiatry. 2023;84:22r14626 https:\/\/doi.org\/10.4088\/JCP.22r14626","journal-title":"J Clin Psychiatry"},{"key":"3256_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-023-01347-3","author":"L Beunk","year":"2023","unstructured":"Beunk L, Nijenhuis M, Soree B, Egberts KM, Fekete S, Gerlach M, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics. Eur J Hum Genet. 2023. https:\/\/doi.org\/10.1038\/s41431-023-01347-3","journal-title":"Eur J Hum Genet"},{"key":"3256_CR13","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/15622975.2024.2366235","volume":"25","author":"XM Hart","year":"2024","unstructured":"Hart XM, Gr\u00fcnder G, Ansermot N, Conca A, Corruble E, Crettol S, et al. Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics. World J Biol Psychiatry. 2024;25:451\u2013536. https:\/\/doi.org\/10.1080\/15622975.2024.2366235","journal-title":"World J Biol Psychiatry"},{"key":"3256_CR14","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2215-0366(23)00002-0","volume":"10","author":"AF Pardi\u00f1as","year":"2023","unstructured":"Pardi\u00f1as AF, Kappel DB, Roberts M, Tipple F, Shitomi-Jones LM, King A, et al. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. Lancet Psychiatry. 2023;10:209\u201319. https:\/\/doi.org\/10.1016\/S2215-0366(23)00002-0","journal-title":"Lancet Psychiatry"},{"key":"3256_CR15","doi-asserted-by":"publisher","first-page":"e92522","DOI":"10.1371\/journal.pone.0092522","volume":"9","author":"H Alwan","year":"2014","unstructured":"Alwan H, Pruijm M, Ponte B, Ackermann D, Guessous D, Ehret G, et al. Epidemiology of masked and white-coat hypertension: the family-based SKIPOGH study. PLoS One. 2014;9:e92522 https:\/\/doi.org\/10.1371\/journal.pone.0092522","journal-title":"PLoS One"},{"key":"3256_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2261-8-6","volume":"8","author":"M Firmann","year":"2008","unstructured":"Firmann M, Mayor V, Vidal PM, Bochud M, P\u00e9coud A, Hayoz D, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6 https:\/\/doi.org\/10.1186\/1471-2261-8-6","journal-title":"BMC Cardiovasc Disord"},{"key":"3256_CR17","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1038\/s41380-023-02082-3","volume":"28","author":"J Sjaarda","year":"2023","unstructured":"Sjaarda J, Delacr\u00e9taz A, Dubath C, Laaboub N, Piras M, Grosu C, et al. Identification of four novel loci associated with psychotropic drug-induced weight gain in a Swiss psychiatric longitudinal study: a GWAS analysis. Mol Psychiatry. 2023;28:2320\u20137. https:\/\/doi.org\/10.1038\/s41380-023-02082-3","journal-title":"Mol Psychiatry"},{"key":"3256_CR18","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/jcp.0b013e3181acc372","volume":"29","author":"E Jaquenoud Sirot","year":"2009","unstructured":"Jaquenoud Sirot E, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, et al. ABCB1 and cytochrome P450 polymorphisms: clinical pharmacogenetics of clozapine. J Clin Psychopharmacol. 2009;29:319\u201326. https:\/\/doi.org\/10.1097\/jcp.0b013e3181acc372","journal-title":"J Clin Psychopharmacol"},{"key":"3256_CR19","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1046\/j.1365-2125.1999.00918.x","volume":"47","author":"A Nordmark","year":"1999","unstructured":"Nordmark A, Lundgren S, Cnattingius S, Rane A. Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples. Br J Clin Pharmacol. 1999;47:397\u2013402. https:\/\/doi.org\/10.1046\/j.1365-2125.1999.00918.x","journal-title":"Br J Clin Pharmacol"},{"key":"3256_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/1389200221999210101233135","volume":"22","author":"J Guo","year":"2021","unstructured":"Guo J, Zhu X, Badawy S, Ihsan A, Liu Z, Xie C, et al. Metabolism and mechanism of human cytochrome P450 enzyme 1A2. Curr Drug Metab. 2021;22:40\u20139. https:\/\/doi.org\/10.2174\/1389200221999210101233135","journal-title":"Curr Drug Metab"},{"key":"3256_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1098725","volume":"13","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Zhao L, Zhou X, Meng X, Zhou X. Role of inflammation, immunity, and oxidative stress in hypertension: new insights and potential therapeutic targets. Front Immunol. 2023;13:1098725 https:\/\/doi.org\/10.3389\/fimmu.2022.1098725","journal-title":"Front Immunol"},{"key":"3256_CR22","doi-asserted-by":"publisher","first-page":"R352","DOI":"10.1186\/bcr798","volume":"6","author":"CC Hong","year":"2004","unstructured":"Hong CC, Tang BK, Hammond GL, Tritchler D, Yaffe M, Boyd NF. Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6:R352\u2013R365. https:\/\/doi.org\/10.1186\/bcr798","journal-title":"Breast Cancer Res"},{"key":"3256_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-57002-9","volume":"9","author":"J Rodr\u00edguez-Morat\u00f3","year":"2019","unstructured":"Rodr\u00edguez-Morat\u00f3 J, Goday A, Langohr K, Pujadas M, Civit E, P\u00e9rez-Ma\u00f1\u00e1 C, et al. Short- and medium-term impact of bariatric surgery on the activities of CYP2D6, CYP3A4, CYP2C9, and CYP1A2 in morbid obesity. Sci Rep. 2019;9:20405 https:\/\/doi.org\/10.1038\/s41598-019-57002-9","journal-title":"Sci Rep"},{"key":"3256_CR24","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/cpt.2146","volume":"109","author":"C Lenoir","year":"2021","unstructured":"Lenoir C, Daali Y, Rollason V, Curtin F, Gloor Y, Bosilkovska M, et al. Impact of acute inflammation on cytochromes P450 activity assessed by the Geneva cocktail. CPT. 2021;109:1668\u201376. https:\/\/doi.org\/10.1002\/cpt.2146","journal-title":"CPT"},{"key":"3256_CR25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1097\/FPC.0b013e3283602876","volume":"23","author":"MM S\u00f6derberg","year":"2013","unstructured":"S\u00f6derberg MM, Haslemo T, Molden E, Dahl ML. Influence of CYP1A1\/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. Pharmacogenet Genom. 2013;23:279\u201385. https:\/\/doi.org\/10.1097\/FPC.0b013e3283602876","journal-title":"Pharmacogenet Genom"},{"key":"3256_CR26","doi-asserted-by":"publisher","first-page":"e1005498","DOI":"10.1371\/journal.pgen.1005498","volume":"11","author":"A Loukola","year":"2015","unstructured":"Loukola A, Buchwald J, Gupta R, Palviainen T, H\u00e4llfors J, Tikkanen E, et al. A Genome-Wide Association Study of a biomarker of nicotine metabolism. PLOS Genet. 2015;11:e1005498 https:\/\/doi.org\/10.1371\/journal.pgen.1005498","journal-title":"PLOS Genet"},{"key":"3256_CR27","doi-asserted-by":"publisher","first-page":"5472","DOI":"10.1093\/hmg\/ddw334","volume":"25","author":"MC Cornelis","year":"2016","unstructured":"Cornelis MC, Kacprowski T, Menni C, Gustafsson S, Pivin E, Adamski J, et al. Genome-wide association study of caffeine metabolites provides new insights to caffeine metabolism and dietary caffeine-consumption behavior. Hum Mol Genet. 2016;25:5472\u201382. https:\/\/doi.org\/10.1093\/hmg\/ddw334","journal-title":"Hum Mol Genet"},{"key":"3256_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00877-z","volume":"13","author":"CE Breeze","year":"2021","unstructured":"Breeze CE, Batorsky A, Lee MK, Szeto MD, Xu X, McCartney DL, et al. Epigenome-Wide Association Study of kidney function identifies trans-ethnic and ethnic-specific loci. Genome Med. 2021;13:74 https:\/\/doi.org\/10.1186\/s13073-021-00877-z","journal-title":"Genome Med"},{"key":"3256_CR29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13293-021-00381-4","volume":"12","author":"AM Inkster","year":"2021","unstructured":"Inkster AM, Yuan V, Konwar C, Matthews AM, Brown CJ, Robinson WP. A cross-cohort analysis of autosomal DNA methylation sex differences in the term placenta. Biol Sex Differ. 2021;12:38 https:\/\/doi.org\/10.1186\/s13293-021-00381-4","journal-title":"Biol Sex Differ"},{"key":"3256_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1055\/a-1625-6388","volume":"55","author":"J De Leon","year":"2022","unstructured":"De Leon J, Schoretsanitis G, Smith RL, Molden E, Solismaa A, Sepp\u00e4l\u00e4 N, et al. An International adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. Pharmacopsychiatry. 2022;55:73\u201386. https:\/\/doi.org\/10.1055\/a-1625-6388","journal-title":"Pharmacopsychiatry"},{"key":"3256_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/17512433.2019.1617695","volume":"12","author":"G Schoretsanitis","year":"2019","unstructured":"Schoretsanitis G, Kane JM, Ruan CJ, Spina E, Hiemke C, de Leon J. A comprehensive review of the clinical utility of and a combined analysis of the clozapine\/norclozapine ratio in therapeutic drug monitoring for adult patients. Expert Rev Clin Pharmacol. 2019;12:603\u201321. https:\/\/doi.org\/10.1080\/17512433.2019.1617695","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3256_CR32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s40263-013-0114-6","volume":"27","author":"WK Kennedy","year":"2013","unstructured":"Kennedy WK, Jann MW, Kutscher EC. Clinically significant drug interactions with atypical antipsychotics. CNS Drugs. 2013;27:1021\u201348. https:\/\/doi.org\/10.1007\/s40263-013-0114-6","journal-title":"CNS Drugs"},{"key":"3256_CR33","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1176\/appi.ajp.2019.18050589","volume":"176","author":"AF Pardi\u00f1as","year":"2019","unstructured":"Pardi\u00f1as AF, Nalmpanti M, Pocklington AJ, Legge SE, Medway C, King A, et al. Pharmacogenomic variants and drug interactions identified through the genetic analysis of clozapine metabolism. Am J Psychiatry. 2019;176:477\u201386. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18050589","journal-title":"Am J Psychiatry"},{"key":"3256_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2147\/PGPM.S114211","volume":"10","author":"PY Takahashi","year":"2017","unstructured":"Takahashi PY, Ryu E, Pathak J, Jenkins GD, Batzler A, Hathcock MA, et al. Increased risk of hospitalization for ultrarapid metabolizers of cytochrome P450 2D6. Pharm Pers Med. 2017;10:39\u201347. https:\/\/doi.org\/10.2147\/PGPM.S114211","journal-title":"Pharm Pers Med"},{"key":"3256_CR35","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2217\/bmm.13.16","volume":"7","author":"G Rua\u00f1o","year":"2013","unstructured":"Rua\u00f1o G, Szarek BL, Villagra D, Gorowski K, Kocherla M, Seip RL, et al. Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark Med. 2013;7:429\u201339. https:\/\/doi.org\/10.2217\/bmm.13.16","journal-title":"Biomark Med"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03256-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03256-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03256-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T10:03:16Z","timestamp":1771408996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41380-025-03256-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,17]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3256"],"URL":"https:\/\/doi.org\/10.1038\/s41380-025-03256-x","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,17]]},"assertion":[{"value":"5 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CBE received honoraria for conferences from Forum pour la formation m\u00e9dicale, Idorsia Pharmaceuticals, Janssen-Cilag, Lundbeck, OM-Pharma, Otsuka, Salmon, Sandoz, Schwabe, Servier, Takeda and Vifor-Pharma, in the past 3 years. MP received honoraria for conferences from Vifor, Astellas, Antaros Medical, Bbraun, NovoNordisk and Boehringer Ingelheim, and for advisory boards from Astellas, Baxter and Boehringer Ingelheim. NA received in the past 3 years honoraria for a conference from Sysmex Suisse AG. FV received in the past 3 years honoraria for teaching CME courses from Forum pour la formation m\u00e9dicale, Barr, Switzerland, teaching CME courses from the Swiss Association of Public Health Administration, Bern, Switzerland, and a conference from Sysmex Suisse AG. SC received in the past 3 years honoraria for teaching CME courses from Forum pour la formation m\u00e9dicale, Barr, Switzerland and for consultancy from the Swiss Health Observatory (OBSAN) of the Swiss Federal Office of Public Health. All authors declare that they have no conflict of interest in relation to the content of this paper.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was carried out in accordance with the Declaration of Helsinki, Swiss law, and local requirements. The study protocols were approved by the Ethics Committees of Vaud, Bern and Geneva with participants giving written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}